Loading stock data…
INMD
$14.41-0.06 (-0.41%)
Market ClosedLast close May 1
InMode Ltd.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
InMode Ltd. in the Healthcare sector is trading at $14.41. The stock is currently 14% below its 52-week high of $16.74, remaining 0.4% below its 200-day moving average. Technical signals show neutral RSI of 60 and bearish MACD signal, explaining why INMD maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 60) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$14.41
Potential Upside
130.5%
Whystock Fair Value$33.22
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$913.00M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
10.08
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.12
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
26.16%
Volume
Today's trading volume
316,032
Recent News
Assessing InMode (INMD) Valuation After Reaffirmed 2026 Revenue Guidance
Guidance confirmation puts InMode in focus InMode (NasdaqGS:INMD) reaffirmed its revenue guidance for the first quarter and full year 2026, projecting US$81.5 million to US$81.7 million for the quarter and US$365 million to US$375 million for the year. See our latest analysis for InMode. Guidance confirmation comes as the 1 month share price return of 7.46% contrasts with a 3 year total shareholder return of a 61.69% loss, suggesting recent momentum is improving from a much weaker longer term...
3 Undervalued Small Caps With Insider Buying Across Regions
Over the last 7 days, the United States market has risen by 4.2%, contributing to a substantial 29% climb over the past year, with earnings forecasted to grow by 16% annually. In this environment, identifying stocks that are both undervalued and have insider buying can present intriguing opportunities for investors seeking potential growth within small-cap sectors.
InMode Flags Slow Aesthetic Demand, Picofy-Driven Q1 Lift and Margin Pressure at Needham Conference
InMode (NASDAQ:INMD) discussed recent operating trends, product launches, margin pressure, and capital allocation during a fireside chat at the 25th Annual Needham Healthcare Conference. Needham & Company’s Mike Matson hosted the session with CEO Moshe Mizrahy and CFO Yair Malca. Q1 performance
InMode CFO Sees Demand Stabilizing, Targets Flat 2026 Revenue as North America Rebuild Begins
InMode (NASDAQ:INMD) CFO Yair Malca said the company believes a multi-year downturn in demand is beginning to stabilize, with management expecting 2026 revenue to be flat after roughly two years of declining business. Speaking at a conference event, Malca emphasized that while pressures remain—parti
InMode Details Israel Disruptions, 60% Capacity and $600M Buyback Plans at Oppenheimer Conference
InMode (NASDAQ:INMD) executives outlined the operational challenges of running the business amid continued geopolitical instability in Israel, while also discussing capital return plans, market conditions for aesthetics, organizational changes, and product strategy during an Oppenheimer conference d